Loading clinical trials...
Loading clinical trials...
A Study on the Safety, Tolerability and Efficacy of MTS109 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases, an Investigator-Initiated Trial
Conditions
Interventions
MTS109
Locations
1
China
Shanghai ChangZheng Hospital
Shanghai, Shanghai Municipality, China
Start Date
March 24, 2026
Primary Completion Date
April 1, 2028
Completion Date
April 1, 2029
Last Updated
April 16, 2026
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT05843643
NCT06333483
Lead Sponsor
Shanghai Changzheng Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions